CRISPR screens identify PRMT7 as a therapeutic target to enhance T cell-mediated killing in breast cancer.

NPJ Breast Cancer · 2026 · PMC12891518 · PMID 41565695

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

did not reach statistical significanceP = 0.1so close (0.05 < p ≤ 0.1)

A similar trend was observed in Luminal A tumors, where high PRMT7/low CD8+ was correlated with shorter survival, although this did not reach statistical significance (log rank P = 0.1).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.